Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database

David P Miller, Stephanie E Watkins, Tim Sampson, Kourtney J Davis, David P Miller, Stephanie E Watkins, Tim Sampson, Kourtney J Davis

Abstract

Objectives: Some large population-based studies have reported a dose-related increased risk of cataracts and glaucoma associated with use of inhaled corticosteroids (ICS) in patients with asthma or chronic obstructive pulmonary disease (COPD). We evaluated the association between use of ICS-containing products, specifically fluticasone propionate/salmeterol fixed-dose combination (FSC), and incidence of cataracts and glaucoma among patients with COPD in a large electronic medical record database in the United Kingdom.

Methods: We identified a cohort of patients aged 45 years and over with COPD in the General Practice Research Database (GPRD) between 2003 and 2006. Cases of incident cataracts or glaucoma were defined based on diagnosis and procedure codes and matched to controls from the risk set to estimate odds ratios (OR) and 95% confidence intervals (CI). The association with FSC or ICS exposure was modeled using conditional logistic regression. Medication exposure was assessed with respect to recency, duration, and number of prescriptions prior to the index date. Average daily dose was defined as none, low (1-250 mcg), medium (251-500 mcg), high (501-1000 mcg), or very high (1001+ mcg) using fluticasone propionate (FP) equivalents.

Results: We identified 2941 incident cataract cases and 327 incident glaucoma cases in the COPD cohort (n = 53,191). FSC or ICS prescriptions were not associated with risk of incident cataracts or glaucoma for any exposure category, after adjusting for confounders. We observed a lack of a dose response in all analyses, where low dose was the reference group. The odds of cataracts associated with FSC dose were medium OR: 1.1 (95% CI: 0.9-1.4); high OR: 1.2 (95% CI: 0.9-1.5); and very high OR: 1.2 (95% CI: 0.9-1.7). The odds of glaucoma associated with FSC dose: medium OR: 1.0 (95% CI: 0.5-2.1); high OR: 1.0 (95% CI: 0.5-2.0); and very high OR: 1.0 (95% CI: 0.4-2.8).

Conclusions: FSC or other ICS exposure was not associated with an increased odds of cataracts or glaucoma, nor was a dose-response relationship observed in this population-based nested case-control study of COPD patients in the United Kingdom.

Keywords: cataracts; fluticasone propionate/salmeterol; glaucoma; inhaled corticosteroids; risk.

Figures

Figure 1
Figure 1
Association between 1 year prior FSC or ICS prescriptions and odds of cataracts: average daily dose analysis. Notes: Reference: low average daily dose. Abreviations: FSC, fluticasone propionate/salmeterol fixed-close combination; ICS, inhaled corticosteroids.
Figure 2
Figure 2
Association between 1 year prior drug exposure and odds of glaucoma: average daily dose analysis. Notes: Reference: low average daily dose. Abbreviation: ICS, inhaled corticosteroids.

References

    1. Anderson HR, Gupta R, Strachan DP, Limb ES. 50 years of asthma: UK trends from 1955 to 2004. Thorax. 2007;62(1):85–90.
    1. Stafford RS, Ma J, Finkelstein SN, Haver K, Cockburn I. National trends in asthma visits and asthma pharmacotherapy, 1978–2002. J Allergy Clin Immunol. 2003;111(4):729–735.
    1. Rabe KF. Guidelines for chronic obstructive pulmonary disease treatment and issues of implementation. Proc Am Thorac Soc. 2006;3(7):641–644.
    1. Skuta GL, Morgan RK. Corticosteroid-induced glaucoma. In: Ritch R, Shields MD, Krupin T, editors. The Glaucomas. St. Louis, MO: Mosby; 1996. pp. 1177–1188.
    1. Becker B, Mills DW. Corticosteroids and intraocular pressure. Arch Ophthalmol. 1963;70(4):500–507.
    1. Mitchell P, Cumming RG, Mackey DA. Inhaled corticosteroids, family history, and risk of glaucoma. Ophthalmology. 1999;106(12):2301–2306.
    1. Gonzalez AV, Li G, Suissa S, Ernst P. Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. Pulm Pharmacol Ther. 2010;23(2):65–70.
    1. Simons FE, Persaud MP, Gillespie CA, Cheang M, Shuckett EP. Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids. Lancet. 1993;342(8874):776–778.
    1. Toogood JH, Markov AE, Baskerville J, Dyson C. Association of ocular cataracts with inhaled and oral steroid therapy during long-term treatment of asthma. J Allergy Clin Immunol. 1993;91(2):571–579.
    1. Abuekteish F, Kirkpatrick JN, Russell G. Posterior subcapsular cataract and inhaled corticosteroid therapy. Thorax. 1995;50(6):674–676.
    1. Sevel D, Weinberg EG, van Niekerk CH. Lenticular complications of long-term steroid therapy in children with asthma and eczema. J Allergy Clin Immunol. 1977;60(4):215–217.
    1. Jick SS, Vasilakis-Scaramozza C, Maier WC. The risk of cataract among users of inhaled steroids. Epidemiology. 2001;12(2):229–234.
    1. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA. 1998;280(6):539–543.
    1. Ernst P, Baltzan M, Deschênes J, Suissa S. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J. 2006;27(6):1168–1174.
    1. Smeeth L, Boulis M, Hubbard R, Fletcher AE. A population based case- control study of cataract and inhaled corticosteroids. Br J Ophthalmol. 2003;87(10):1247–1251.
    1. Weatherall M, Clay J, James K, Perrin K, Shirtcliffe P, Beasley R. Dose- response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology. 2009;14(7):983–990.
    1. Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology. 2009;116(4):652–657.
    1. Lawson DH, Sherman V, Hollowell J. The general practice research database. Scientific and ethical advisory group. QJM. 1998;91(6):445–452.
    1. Nazareth I, King M, Haines A, Rangel L, Myers S. Accuracy of diagnosis of psychosis on general practice computer system. BMJ. 1993;307(6895):32–34.
    1. Hansell A, Hollowell J, Nichols T, McNiece R, Strachan D. Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4) Thorax. 1999;54(5):413–419.
    1. Soriano JB, Maier WC, Egger P, et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax. 2000;55(9):789–794.
    1. Soriano JB, Maier WC, Visick G, Pride NB. Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database. Eur J Epidemiol. 2001;17(12):1075–1080.
    1. Chylack LT, Jr, Gross GN, Pedinoff A. A randomized, controlled trial to investigate the effect of ciclesonide and beclomethasone dipropionate on eye lens opacity. J Asthma. 2008;45(10):893–902.
    1. Van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales. Bone. 2001;29(6):517–522.
    1. Garbe E, Boivin JF, LeLorier J, Suissa S. Selection of controls in database case-control studies: glucocorticoids and the risk of glaucoma. J Clin Epidemiol. 1998;51(2):129–135.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir